Voyager to Present Preclinical Data of VY-HTT01 & VY-SOD102 at ESGCT 2018

Shots:

• Voyager’s program for Huntington’s Disease and Amyotrophic Lateral Sclerosis assessing VY-HTT01 at five wks. post-dosing in adult non-human primates & VY-SOD102 one-time intraparenchymal infusion after laminectomy
• The program demonstrated reduction in HTT mRNA by 68% in the caudate, 67% in the putamen, 73% in the thalamus, and 32% in cortical neurons & reduction in SOD1 mRNA in the spinal cord by 70% & 50% in the cervical and thoracic regions, 82% near the site of cervical injection & 22% in the lumbar region
• VY-SOD102 & VY-HTT01 is composed of an adeno-associated virus capsid (AAVrh10) & adeno-associated virus capsid (AAV1) respectively. The preclinical data will support its IND application in 2019

Click here to read full press release/ article | Ref: Voyager Therapeutics | Image:  Market Exclusive